(A) shows the dose response curves for the intracellular expression of mMCP-1 as assessed by immunohistochemical staining of cytosmears with MoAb RF 6.1 for mBMMC cultures set up in WEHI (15%)/rrSCF (50 ng/mL) alone (⧫) or in WEHI/rrSCF with 0.5 ng/mL (□), 5 ng/mL (▴), or 25 ng/mL (○) rmIL-9. (B) shows the concentrations of mMCP-1 in supernatants from the mBMMC cultures described in (A). (C) and (D) show expression of mMCP-1 in short-term bone marrow cultures in which cells were cultured for 7 days in the presence of WEHI/rrSCF (>90% mBMMC; >98% viable), before they were transferred to separate flasks and cultured for a further 7 days in quadruplicate in the presence of either WEHI/rrSCF or rmIL-9/rrSCF. In (C), percentages of mMCP-1⁺ (▵, ○) and chymase⁺ (•, ▾) mast cells were assessed by immunohistochemical staining of cytosmears using MoAb RF 6.1 or sheep polyclonal antibody that cross–reacts with other chymases. Results are shown from mBMMC cultured in WEHI/rrSCF (▾, ○) or rmIL-9/rrSCF (•, ▵). In (D), the concentration of mMCP-1 in supernatants was assessed in quadruplicate mBMMC cultures grown in WEHI/rrSCF (▪) or rmIL-9/rrSCF (▵). Data are expressed as the mean ± SE.